IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: T. Kolasa, et al.

Serial No.: (not yet assigned)

Filed: February 5, 2004

For: OXIMES AND HYDRAZONES THAT ARE USEFUL IN TREATING SEXUAL

DYSFUNCTION

Attorney Docket No.: 7283.US.01

Examiner: (not yet assigned)

Group Art Unit: (not yet assigned)

EXPRESS MAIL NO.: EV 314261260US

Certificate of Mailing under 37 CFR §1.10:

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office to Addressee

Service with sufficient postage in an envelope

addressed as follows:

MS Patent Application Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Date of Deposit: You Hermann 2-5.2004 Keri Hermann

INFORMATION DISCLOSURE STATEMENT

MS Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The following information is submitted, pursuant to 37 CFR §§1.97-1.98 in accordance with Applicant's duty of disclosure under 37 CFR §1.56. This submission is not intended to constitute an admission that any patent, publication or other information cited herein is "prior art" as to the invention claimed. In accordance with 37 CFR §§1.97(g)-(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that other material information as defined by 37 CFR §1.56(a) exists.

Applicants submit herewith Form PTO-1449 listing the references known to them. Applicants respectfully request that the Examiner (1) initial each reference listed on the enclosed Form PTO-1449 indicating that the Examiner has considered and made those references of record in this application and (2) return a copy of the initialed Form PTO-1449 to Applicants. Copies of the references are also enclosed.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits under 37 CFR §1.97(b). Accordingly, no charge is required.

Respectfully submitted,

T. Kolasa, et al.

ABBOTT LABORATORIES

Customer No.: 23492 Telephone: (847) 935-4314 Facsimile: (847) 938-2623

Gabryleda Ferrari-Dileo Registration No. P55,174 Attorney for Applicants DATE: February 5, 2004

C1	N PATENT OI MENT NUMBER	U.S.	ISSUE DATE	7283.US.01 APPLICANT(S) T. Kolasa, et al. FILING DATE February 5, 200 OCUMENTS INVENTOR FOREIGN PATENT COUNTRY OR	CLASS	Not a	ssigned y		
C1	TENT NUMBER N PATENT OI MENT NUMBER	U.S.	ISSUE DATE DATE DBLISHED JBLIC-ATION	T. Kolasa, et al. FILING DATE February 5, 200 OCUMENTS INVENTOR FOREIGN PATENT	CLASS	Not a	ssigned y	FILING	
(Use several (37 CFR 1.98 (b)) EXAMINER INITIAL PA' FOREIGN DOCUM B1 1,384,522 B2 1,378,086 C1 Andersso C2 Hrib, N., C3 DeGroat, Publisher C4 Dula, E. oplacebo i C5 Milligan, (1998) C6 Missale, underson C7 Morales, America, C8 Moreland, Drugs, 2: C9 Padma-N	TENT NUMBER N PATENT OI MENT NUMBER	U.S.	ISSUE DATE DATE DBLISHED JBLIC-ATION	FILING DATE February 5, 200 OCUMENTS INVENTOR FOREIGN PATENT	CLASS	Not a	ssigned y	FILING	
STAMINER PA' PA'	TENT NUMBER N PATENT OI MENT NUMBER 3	R PU	ISSUE DATE DATE DBLISHED JBLIC-ATION	February 5, 200 OCUMENTS INVENTOR FOREIGN PATENT	CLASS	Not a	ssigned y	FILING	
STAMINER PA' PA'	TENT NUMBER N PATENT OI MENT NUMBER 3	R PU	ISSUE DATE DATE DBLISHED JBLIC-ATION	INVENTOR FOREIGN PATENT	CLASS	SUE	B I	FILING	
FOREIGN	N PATENT OI MENT NUMBER	R PU	ISSUE DATE DATE DBLISHED JBLIC-ATION	INVENTOR FOREIGN PATENT		CLAS	SS		
FOREIGN	N PATENT OI MENT NUMBER	R PU	ISSUE DATE DATE DBLISHED JBLIC-ATION	INVENTOR FOREIGN PATENT		CLAS	SS		
FOREIGN	N PATENT OI MENT NUMBER	PU	JBLISHED JBLIC-ATION	FOREIGN PATENT		CLAS	SS		
DOCUI	N PATENT OI MENT NUMBER	PU	JBLISHED JBLIC-ATION	FOREIGN PATENT					
DOCUI B1	MENT NUMBER 3	PU	JBLIC-ATION		APPLI	CATIO	Ň		
DOCUI B1	MENT NUMBER 3	PU	JBLIC-ATION		APPLI	CATIO	N		
B1	3			COUNTRY OR					
B1	3		DATE	COUNTRY OR			CI TO	TRANS-	
DTH C1 Andersso C2 Hrib, N., C3 DeGroat, Publisher C4 Dula, E. o placebo i C5 Milligan, (1998) C6 Missale, C7 Morales, America, C8 Moreland Drugs, 2: C9 Padma-N)	02		PATENT OFFICE		CLASS	SUB CLASS	YES N	
C1 Andersso C2 Hrib, N., C3 DeGroat, Publisher C4 Dula, E. o placebo i C5 Milligan, (1998) C6 Missale, C7 Morales, America, C8 Moreland Drugs, 2: C9 Padma-N			2/19/75	Great Britain	<u> </u>				
C1 Andersso C2 Hrib, N., C3 DeGroat, Publisher C4 Dula, E. o placebo i C5 Milligan, (1998) C6 Missale, C7 Morales, America, C8 Moreland Drugs, 2: C9 Padma-N	IED DOOLEG	12	2/18/74	Great Britain					
C1 Andersso C2 Hrib, N., C3 DeGroat, Publisher C4 Dula, E. o placebo i C5 Milligan, (1998) C6 Missale, C7 Morales, America, C8 Moreland Drugs, 2: C9 Padma-N		FNT	'S (Including	Author, Title, Date, Place	of Publica	tion)			
C3 DeGroat, Publisher C4 Dula, E. o placebo i C5 Milligan, (1998) C6 Missale, C7 Morales, America, C8 Moreland Drugs, 2: C9 Padma-N				tion," Physiol. Rev. 75:191					
Publisher C4 Dula, E. o placebo i C5 Milligan, (1998) C6 Missale, C7 Morales, America, C8 Moreland Drugs, 2: C9 Padma-N	"The dopamine D	4 rece	ptor: a controv	versial therapeutic target", l	Orugs of the	Future: 2	5:587-611	(2000)	
C4 Dula, E. o placebo i C5 Milligan, (1998) C6 Missale, C7 Morales, America, C8 Moreland Drugs, 2: C9 Padma-N	DeGroat, W. et al., "Neural Control of Penile Erection, in: Nervous control of urogenital system," Hardwood Academic Publishers, Chur, Switzerland, Vol. 3 (ed. Maggi, C.):467-524 (1993)								
C5 Milligan, (1998) C6 Missale, C7 Morales, America, C8 Moreland Drugs, 2: C9 Padma-N	Dula, E. et al., "Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction," Urology 56:130-135 (2000)								
C6 Missale, C7 Morales, America, C8 Moreland Drugs, 2: C9 Padma-N	G. et al., "Chimae	eric G	proteins: their	potential use in drug disco	very," Tren	ds Pharma	icol Sci 20:	118-124	
C8 Moreland Drugs, 2: C9 Padma-N	C. et al. "Dopamin	ne rece	eptors: from str	ucture to function," Physic	l Rev 78:18	39-225 (19	998)		
C8 Moreland Drugs, 2: C9 Padma-N	Morales, A. et al., "Oral and Topical Treatment of Erectile Dysfunction: present and future," Urologic Clinics of North America, vol. 22:879-886 (1995)								
C9 Padma-N	l, RB, et al., "Pros 283-302 (2000)	pectiv	es for Pharmac	cotherapy of Male Erectile	Dysfunction	ı," Curr C	Opinion CPI	NS Invest	
1 101:714	Padma-Nathan, H. et al., "Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction," Urology 161:214 (abstract 821) (1999)								
C10 Primus, F	R. et al., "Localizat	tion ar	d [³HINGD 94	tion of dopamine D ₄ binding 1," J. Pharmacol Exp. The	r 282:1020	-1027 (199	97)		
C11 Melis M.	, et al., "Dopamine	e and s	sexual behavio	r", Neuroscience and Beha	vioral Revi	ews 19: 19	9-38 (1995)		
C12 Suzuki, N	A. et al., "D₃ dopar	mine r	receptor mRNA	A is widely express in huma	ın brain," B	rian Res 7	779:58-74 (1	1998)	
C13 Vallone,	D. et al., "Structur	e and	function of do	pamine receptors," Neuros	ci Biobehav	, Rev. 24:	:125-132 (2	000)	
				ine, gamma hydroxybutiru 214:427-432 (1980)	c acid, halo	peridol, ar	nd pimozide	on reflex	
C15 Hahn R.A	bradicardia in rats", J. Pharmacol. Exp. Therap. 214:427-432 (1980) Hahn R.A. et al., "Primate cardiovascular responses mediated by dopaminergic receptors: effects of N,N-dihydrodopamine and LY171555" J. Pharmacol Exp. Therap. 229:132-138 (1984)								
C16 Bendele				ergolide, a dopamine recep		, J. Pharm	acol Exp. T	herap.	
C17 Lissoni e	t al., "Efficacy of b			treatment of metastatic breers 21:405-408 (2000)	ast cancer a	nd prostat	e cancer-re	ated	
C18 Martinez	-Esparza et al., "N	ew 1-	Aryl-3-(4-aryl)	piperazin-1-yl)propane deri lass of antidepressant" J. M				A Serotonin	
EXAMINER	s and Serotonin tra		,	DATE CONSIDERED					

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE: February 5, 2004

Form PTO - 1449 (Modified) FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO. SERIAL NO. (Modified) 7283.US.01 Not assigned yet APPLICANT(S) INFORMATION DISCLOSURE STATEMENT BY APPLICANT T. Kolasa, et al. GROUP FILING DATE (Use several sheets if necessary) February 5, 2004 Not assigned yet (37 CFR 1.98 (b)) **U.S.PATENT DOCUMENTS** FILING SUB **EXAMINER** ISSUE PATENT NUMBER **INVENTOR CLASS CLASS** INITIAL DATE DATE FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION PUBLIC-ATION TRANS-DOCUMENT NUMBER COUNTRY OR **SUB LATION** DATE PATENT OFFICE CLASS **CLASS** YES NO Bl 1,384,523 02/19/75 Great Britain 1,378,080 B2 12/18/74 Great Britain OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) Andersson, K. et al., "Physiology of penile erection," Physiol. Rev. 75:191-236 (195) CI Hrib, N., "The dopamine D4 receptor: a controversial therapeutic target", Drugs of the Future: 25:587-611 (2000) C2 DeGroat, W. et al., "Neural Control of Penile Erection, in: Nervous control of urogenital system," Hardwood Academic C3 Publishers, Chur, Switzerland, Vol. 3 (ed. Maggi, C.):467-524 (1993) C4 Dula, E. et al., "Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction," Urology 56:130-135 (2000) Milligan, G. et al., "Chimaeric G proteins: their potential use in drug discovery," Trends Pharmacol Sci 20:118-124 C5 (1998)Missale, C. et al. "Dopamine receptors: from structure to function," Physiol Rev 78:189-225 (1998) <u>C6</u> C7 Morales, A. et al., "Oral and Topical Treatment of Erectile Dysfunction: present and future," Urologic Clinics of North America, vol. 22:879-886 (1995) Moreland, RB, et al., "Prospectives for Pharmacotherapy of Male Erectile Dysfunction," Curr Opinion CPNS Invest C8 Drugs, 2:283-302 (2000) C9 Padma-Nathan, H. et al., "Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction," Urology 161:214 (abstract 821) (1999) C10 Primus, R. et al., "Localization and characterization of dopamine D₄ binding sites in rat and human brain by use of the novel D₄ receptor-selective ligand [³H]NGD 94-1," J. Pharmacol Exp. Ther 282:1020-1027 (1997) CII Melis M., et al., "Dopamine and sexual behavior", Neuroscience and Behavioral Reviews 19: 19-38 (1995) C12 Suzuki, M. et al., "D₃ dopamine receptor mRNA is widely express in human brain," Brian Res 779:58-74 (1998) C13 Vallone, D. et al., "Structure and function of dopamine receptors," Neurosci Biobehav. Rev. 24:125-132 (2000) C14 Chen F., et al., "Effects of dopamine, apomorphine, gamma hydroxybutiruc acid, haloperidol, and pimozide on reflex bradicardia in rats", J. Pharmacol. Exp. Therap. 214:427-432 (1980) C15 Hahn R.A. et al., "Primate cardiovascular responses mediated by dopaminergic receptors: effects of N,Ndihydrodopamine and LY171555" J. Pharmacol Exp. Therap. 229:132-138 (1984) C16 Bendele et al., "Anti-inflammatory activity of pergolide, a dopamine receptor agonist", J. Pharmacol Exp. Therap. 259:169-175 (1991) C17 Lissoni et al., "Efficacy of bromocriptine in the treatment of metastatic breast cancer and prostate cancer-related hyperprolactinemia", Neuroendocrinology Letters 21:405-408 (2000) Martinez-Esparza et al., "New 1-Aryl-3-(4-arylpiperazin-1-yl)propane derivatives with dual action at 5-HT_{1A} Serotonin C18 Receptors and Serotonin transporter, as a new class of antidepressant" J. Med. Chem. 44:418-428 (2001) **EXAMINER DATE CONSIDERED**